Sanofi-Aventis, which briefly faced generic competition to its second-biggest product Plavix in the United States in 2006 and 2007, now faces a similar threat in Europe.

Too few influential doctors are telling the public if they have financial ties to the companies that make lifesaving drug-coated stents.

Financial pain and physical pain may be linked: A new study says people who make less money and work in blue-collar jobs are more prone to be in pain.

Merck says it has received a warning letter from the Food and Drug Administration over concerns at one of its major vaccine manufacturing plants.

Genentech and Biogen Idec said a key study of Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus.

U.S. health regulators have rejected a new drug from Merck that was designed to raise the level of HDL, or "good" cholesterol, the company said, sending its shares plunging more than 10 percent.

Schering-Plough, whose shares have been battered this year by a failed trial of its Vytorin cholesterol drug, reported a smaller-than-expected drop in quarterly earnings on Wednesday thanks to cost controls.

Merck and Eli Lilly reported earnings today, and CNBC asked the pharmaceutical companies’ chief executives and an analyst to discuss the results and the sector as a whole.

Genentech's blockbuster cancer drug Avastin faces a big challenge from ImClone Systems's Erbitux in lung cancer, Morgan Stanley analysts said on Monday, citing unpublished data.

Genentech reported earnings that edged forecasts, but sales of all four of its big brand-name drugs fell short of forecasts.

Takeda Pharmaceutical said it would buy U.S. firm Millennium Pharmaceuticals for $8.8 billion to boost its cancer drug business, in the biggest overseas acquisition by a Japanese drug maker.

Pfizer and Nektar Therapeutics said Wednesday clinical trials of the inhaled insulin Exubera found increased cases of lung cancer, leading Nektar to end talks with potential partners to market the product.

Options activity is picking up in Johnson & Johnson stock. Why?

Walgreen posted a 4.4 percent increase in sales at stores open at least a year as strong demand for Easter merchandise helped offset tepid sales growth for prescription drugs.